Adamas Announces FDA Approval for Second Indication for Gocovri as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes 03/02/2021 mediabest Medications EMERYVILLE, Calif.–(BUSINESS WIRE)–Feb. 1, 2021– Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make Read more